Literature DB >> 26501392

Involvement of cytokines in the modulation and progression of renal fibrosis induced by unilateral ureteral obstruction in C57BL/6 mice: effects of thalidomide and dexamethasone.

Luiz Eduardo Bersani-Amado1, Jaílson Araujo Dantas2, Marcio José Damião2, Bruno Ambrósio Rocha2, Jean Carlos Fernando Besson3, Rafael Lucena Bastos4, Letícia Nicoletti Silva5, Ciomar Aparecida Bersani-Amado2, Roberto Kenji Nakamura Cuman2.   

Abstract

This study investigated the kinetics of cytokines that are involved in the development of interstitial fibrosis in mice that were subjected to UUO, the interstitial type I and III collagen deposition, and the effects of Thalido and Dexa treatment on these parameters. Inbred C57BL/6 mice were divided into the groups: Normal (not submitted surgery), Sham (sham surgery), Control (UUO treated with 0.5% carboxymethyl cellulose), Thalido (UUO treated with 5 mg/kg thalidomide), and Dexa (UUO treated with 1 mg/kg dexamethasone). The treatments began the day before surgery and were administered once daily by gavage for 1, 7, or 14 days. At the end of each treatment period, blood samples were collected for the determination of creatinine, urea, cytokines. The Control group exhibited a increase in creatinine concentration compared with the Normal and Sham groups within the first 24 h after UUO, which remained high until days 7 and 14. The urea concentration was higher on days 7 and 14 in the Control group compared with the Sham group. In the Thalido and Dexa groups, a reduction of serum creatinine concentration was seen on day 14. Treatment with Dexa reduced the serum concentration of urea on day 7. The serum concentrations of cytokines (TNF-α, IL-1β, IL-6, IL-10 and IL-17) and chemokines (KC, MIG, bFGF) increased in UUO mice at all of the sampling times. The Dexa and Thalido groups exhibited alterations in the concentrations of these cytokines, suggesting the involvement of anti-inflammatory and immunomodulatory mechanisms that may have modified the fibrosis framework.
© 2015 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Keywords:  cytokines; dexamethasone; renal function; renal interstitial fibrosis; thalidomide

Mesh:

Substances:

Year:  2015        PMID: 26501392     DOI: 10.1111/fcp.12162

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  5 in total

1.  Enhanced immune-modulatory effects of thalidomide and dexamethasone co-treatment on T cell subsets.

Authors:  Eun Jee Kim; Jae Geun Lee; Joon Ye Kim; Seung Hwan Song; Dong Jin Joo; Kyu Ha Huh; Myoung Soo Kim; Beom Seok Kim; Yu Seun Kim
Journal:  Immunology       Date:  2017-08-23       Impact factor: 7.397

2.  Dexamethasone exacerbates cytotoxic chemotherapy induced lethargy and weight loss in female tumor free mice.

Authors:  John Wong; Lisa T Tran; Kaari A Lynch; Lisa J Wood
Journal:  Cancer Biol Ther       Date:  2017-12-12       Impact factor: 4.742

3.  Screening of genes involved in epithelial-mesenchymal transition and differential expression of complement-related genes induced by PAX2 in renal tubules.

Authors:  Xiu-Li Wang; Ling Hou; Cheng-Guang Zhao; Ying Tang; Bo Zhang; Jing-Ying Zhao; Yu-Bin Wu
Journal:  Nephrology (Carlton)       Date:  2018-03-24       Impact factor: 2.506

4.  Baicalin protects against renal interstitial fibrosis in mice by inhibiting the TGF-β/Smad signalling pathway.

Authors:  Hui Wang; Qingtao Jiang; Lizhu Zhang
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

5.  Transcriptomics Study to Determine the Molecular Mechanism by which sIL-13Rα2-Fc Inhibits Caudal Intervertebral Disc Degeneration in Rats.

Authors:  Xin Wang; Jianshi Tan; Junhao Sun; Pengzhong Fang; Jinlei Chen; Wen Yuan; Huajiang Chen; Yang Liu
Journal:  Biomed Res Int       Date:  2020-08-14       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.